In Con1 genotype 1b subgenomic replicon cells, 48-h VX-950 exposure gave an HCV RNA IC50 of 0.354 ± 0.035 μM and IC90 of 0.830 ± 0.190 μM in 2% FBS (mean ± SD, three independent experiments). The matched viability CC50 was 83 ± 27 μM. These model-specific assay values do not establish clinical efficacy. [2]
Human serum reduced the apparent cellular potency of VX-950: the 48-h RNA IC50 rose from 0.33 μM without added human serum to 3.45 μM with 40% human serum. Serum composition therefore matters when comparing potency values across assay conditions. [2]
Reversible, slow-dissociating inhibition of genotype 1a NS3-4A
Biochemical assay · Purified HCV H-strain (genotype 1a) NS3 protease domain with KK4A cofactor peptide [1]
VX-950 formed a covalent, reversible inhibited complex. Steady-state binding and dissociation were measured separately within the enzyme-kinetics characterization.
Literature-Reported Treatment Conditions
- Exposure duration
- Steady-state rates at 4 h; dissociation followed over a 4-h window
- Method
- Fluorescent peptide-cleavage kinetics; Morrison tight-binding fit for Ki* and dilution-based recovery of activity for dissociation
- Vehicle
- 2% DMSO
- Reported limits
- No variance or replicate count reported for the quoted Ki* and complex half-life. Ki* is not an IC50.
Methods and source locations
Compound reported in the paper: Telaprevir (VX-950); Compound label in the paper: VX-950
Applies to the named compound and the genotype 1a enzyme assay; does not establish universal genotype potency.
Materials; Figure 1A-B; Table 1 identity/footnote; fluorescence cleavage methods; Results: VX-950 forms a tight, long-lived complex
Steady-state inhibition of H-strain genotype 1a NS3-4A: Fluorescent peptide cleavage; steady-state rate at 4 h; Morrison equation; DMSO control — Fluorescence peptide cleavage methods; Results: VX-950 forms a tight, long-lived complex, first paragraph
Dissociation half-life of the inhibited enzyme complex: Recovery of peptide-cleavage activity after dilution; no-inhibitor DMSO control — Fluorescence peptide cleavage methods; Results: VX-950 forms a tight, long-lived complex, first paragraph
Acute replicon inhibition with matched cytotoxicity evaluation
Cell-based study · Con1 genotype 1b subgenomic HCV replicon cells in Huh-7 background [2]
VX-950 reduced cellular HCV RNA in a time-dependent manner. Three independent 48-h experiments supplied the RNA inhibition estimates. The accompanying MTS viability CC50 was much higher; its independent-experiment count is not separately stated. Figure 2 is a representative time-course concentration series, not the three-experiment aggregate.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h for aggregate IC50, IC90 and CC50
- Method
- Quantitative RT-PCR RNA endpoint with parallel MTS cell viability assay; 2% FBS
- Vehicle
- 0.5% DMSO (no-compound control)
- Reported limits
- Dose range for the aggregate three-experiment fit is not enumerated with those aggregate estimates; do not substitute the representative Figure 2 range.
Methods and source locations
Compound reported in the paper: Telaprevir (VX-950); Compound label in the paper: VX-950
Cellular RNA inhibition and viability endpoints in a subgenomic model; no clinical efficacy inference.
Materials; Determination of anti-HCV activity and cytotoxicity; first Results subsection; Figure 2 and caption
Reduction in cellular HCV RNA: 48-h assay in 2% FBS; 3 independent experiments; RNA by quantitative RT-PCR, viability by MTS — Results: VX-950 reduced HCV RNA levels in replicon cells in a time- and dose-dependent manner, first paragraph
Reduction in cellular HCV RNA: 48-h assay in 2% FBS; 3 independent experiments; RNA by quantitative RT-PCR, viability by MTS — Results: VX-950 reduced HCV RNA levels in replicon cells in a time- and dose-dependent manner, first paragraph
Loss of replicon-cell viability: 48-h MTS viability assay in 2% FBS; mean ± SD; independent-experiment count for CC50 not separately stated — Results: VX-950 reduced HCV RNA levels in replicon cells in a time- and dose-dependent manner, first paragraph
Human-serum-dependent loss of apparent cellular potency
Cell-based study · Con1 genotype 1b subgenomic HCV replicon cells with 0%, 10%, 20% or 40% added human serum [2]
Increasing human serum shifted the 48-h RNA inhibition endpoints upward. No-compound controls were included at the serum conditions; the authors report that serum alone had little, if any, effect on RNA levels. This experiment limits extrapolation from low-serum potency.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.03, 0.1, 0.3, 1, 3 or 10 μM
- Exposure duration
- 48 h
- Method
- Quantitative RT-PCR; comparison across human-serum conditions
- Vehicle
- 0.5% DMSO control
- Reported limits
- No replicate count or uncertainty supplied in Table 1. Serum CC50 entries are not adopted: the footnote lists an antiviral concentration series ending at 10 μM, while cytotoxicity bounds extend above that range; a separate toxicity series is not specified there.
Methods and source locations
Compound reported in the paper: Telaprevir (VX-950); Compound label in the paper: VX-950
Potency shifts in this cellular assay only; no human-dose prediction.
Effect of human serum on anti-HCV activity of VX-950; Table 1 and footnote
48-h RNA inhibition IC50 at 0%, 10%, 20%, 40% human serum: 48-h quantitative RT-PCR assay; Table 1 supplies no error estimates — Table 1, IC50 column and footnote a
48-h RNA inhibition IC90 at 0%, 10%, 20%, 40% human serum: 48-h quantitative RT-PCR assay; Table 1 supplies no error estimates — Table 1, IC90 column and footnote a